| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin-Like Growth Factor I | 11 | 2013 | 85 | 1.790 |
Why?
|
| Kearns-Sayre Syndrome | 2 | 2017 | 2 | 1.060 |
Why?
|
| Adipocytes | 6 | 2013 | 268 | 0.970 |
Why?
|
| Intra-Abdominal Fat | 2 | 2013 | 34 | 0.720 |
Why?
|
| Human Growth Hormone | 3 | 2016 | 19 | 0.690 |
Why?
|
| Growth Disorders | 2 | 2016 | 29 | 0.610 |
Why?
|
| Obesity | 6 | 2013 | 1234 | 0.570 |
Why?
|
| Dwarfism, Pituitary | 1 | 2017 | 1 | 0.540 |
Why?
|
| Mitochondrial Diseases | 1 | 2017 | 22 | 0.520 |
Why?
|
| src-Family Kinases | 4 | 2007 | 64 | 0.510 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 29 | 0.510 |
Why?
|
| Metabolic Syndrome | 3 | 2008 | 142 | 0.500 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 13 | 0.480 |
Why?
|
| Diabetes, Gestational | 3 | 2008 | 140 | 0.480 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 8 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2007 | 126 | 0.470 |
Why?
|
| Dyslipidemias | 1 | 2015 | 37 | 0.470 |
Why?
|
| Biomarkers | 1 | 2021 | 1408 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 698 | 0.450 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2013 | 12 | 0.410 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2013 | 56 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 207 | 0.390 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 141 | 0.390 |
Why?
|
| Epidermal Growth Factor | 3 | 2010 | 47 | 0.380 |
Why?
|
| Child | 14 | 2024 | 4527 | 0.370 |
Why?
|
| Pediatricians | 2 | 2024 | 53 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 616 | 0.350 |
Why?
|
| Cell Differentiation | 5 | 2003 | 1350 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2018 | 621 | 0.340 |
Why?
|
| Cell Division | 7 | 2003 | 450 | 0.340 |
Why?
|
| Adipocytes, White | 1 | 2010 | 27 | 0.330 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 10 | 0.320 |
Why?
|
| Subcutaneous Fat | 1 | 2010 | 47 | 0.320 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2007 | 429 | 0.300 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2000 | 81 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2005 | 217 | 0.290 |
Why?
|
| Mutation | 3 | 2015 | 2611 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 56 | 0.260 |
Why?
|
| Adipogenesis | 1 | 2007 | 79 | 0.250 |
Why?
|
| Humans | 27 | 2024 | 63549 | 0.250 |
Why?
|
| Stem Cells | 2 | 2000 | 257 | 0.240 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 14 | 0.230 |
Why?
|
| Fetal Macrosomia | 1 | 2005 | 13 | 0.230 |
Why?
|
| Birth Weight | 1 | 2005 | 85 | 0.220 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 70 | 0.220 |
Why?
|
| Child Health | 1 | 2024 | 31 | 0.210 |
Why?
|
| Adolescent | 9 | 2018 | 6249 | 0.210 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2003 | 9 | 0.210 |
Why?
|
| 3T3-L1 Cells | 3 | 2010 | 90 | 0.200 |
Why?
|
| 3T3 Cells | 5 | 2003 | 110 | 0.200 |
Why?
|
| Enzyme Activation | 5 | 2010 | 381 | 0.190 |
Why?
|
| Mice | 12 | 2010 | 10840 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2010 | 3031 | 0.180 |
Why?
|
| Personnel Turnover | 1 | 2021 | 22 | 0.180 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2018 | 12 | 0.180 |
Why?
|
| Repressor Proteins | 2 | 2010 | 345 | 0.180 |
Why?
|
| Endocrinologists | 1 | 2020 | 5 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2021 | 138 | 0.170 |
Why?
|
| Female | 14 | 2018 | 32967 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 226 | 0.160 |
Why?
|
| Phosphorylation | 3 | 2013 | 936 | 0.160 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2018 | 2 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 71 | 0.150 |
Why?
|
| Mitosis | 1 | 2000 | 218 | 0.150 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 3 | 2007 | 4 | 0.140 |
Why?
|
| Shc Signaling Adaptor Proteins | 3 | 2007 | 5 | 0.140 |
Why?
|
| Mitogens | 1 | 1998 | 10 | 0.140 |
Why?
|
| Male | 16 | 2018 | 29956 | 0.140 |
Why?
|
| Animals | 14 | 2010 | 20664 | 0.140 |
Why?
|
| Proteins | 2 | 2000 | 750 | 0.130 |
Why?
|
| Growth Hormone | 1 | 2017 | 18 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2008 | 156 | 0.130 |
Why?
|
| Body Height | 1 | 2016 | 66 | 0.130 |
Why?
|
| Graves Disease | 2 | 2009 | 16 | 0.120 |
Why?
|
| Carrier Proteins | 3 | 1994 | 707 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 138 | 0.120 |
Why?
|
| Melena | 1 | 2015 | 5 | 0.120 |
Why?
|
| Xanthomatosis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2016 | 120 | 0.120 |
Why?
|
| Heterozygote | 1 | 2015 | 170 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2008 | 55 | 0.110 |
Why?
|
| Exons | 1 | 2015 | 199 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 137 | 0.110 |
Why?
|
| Blotting, Northern | 4 | 2000 | 150 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 305 | 0.110 |
Why?
|
| Lipopeptides | 1 | 2013 | 15 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 14 | 0.100 |
Why?
|
| Anthracenes | 1 | 2013 | 15 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2016 | 364 | 0.100 |
Why?
|
| Omentum | 1 | 2013 | 13 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 477 | 0.100 |
Why?
|
| Klinefelter Syndrome | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hypopituitarism | 1 | 2013 | 3 | 0.100 |
Why?
|
| Puberty, Precocious | 1 | 2013 | 10 | 0.100 |
Why?
|
| Gene Expression | 2 | 2015 | 840 | 0.100 |
Why?
|
| Vascular Calcification | 1 | 2013 | 26 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2008 | 205 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2014 | 484 | 0.090 |
Why?
|
| Pregnancy | 4 | 2008 | 2334 | 0.090 |
Why?
|
| Risk Factors | 4 | 2015 | 5362 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 177 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 1994 | 295 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 373 | 0.090 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2010 | 24 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2018 | 1360 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 431 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2018 | 1994 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2010 | 7 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 38 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 1996 | 895 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 1996 | 1617 | 0.080 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2009 | 4 | 0.080 |
Why?
|
| Insulin | 4 | 2010 | 686 | 0.080 |
Why?
|
| Adrenal Glands | 1 | 2010 | 33 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2013 | 412 | 0.080 |
Why?
|
| Fetus | 1 | 2010 | 99 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 317 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 182 | 0.080 |
Why?
|
| Infant | 2 | 2018 | 1650 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 189 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 34 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2008 | 188 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2010 | 193 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 1996 | 517 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2010 | 392 | 0.070 |
Why?
|
| Infant, Premature | 1 | 2010 | 184 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 171 | 0.070 |
Why?
|
| DNA | 3 | 2001 | 837 | 0.070 |
Why?
|
| Dimerization | 1 | 2007 | 145 | 0.060 |
Why?
|
| Hypoglycemia | 2 | 2017 | 65 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 149 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2007 | 115 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2008 | 768 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2155 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5699 | 0.060 |
Why?
|
| Adult | 3 | 2013 | 16869 | 0.060 |
Why?
|
| Kinetics | 2 | 1998 | 763 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2005 | 8 | 0.060 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2005 | 13 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Body Size | 1 | 2005 | 23 | 0.060 |
Why?
|
| Antibodies, Blocking | 1 | 2005 | 39 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 863 | 0.060 |
Why?
|
| Social Class | 1 | 2005 | 136 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1258 | 0.050 |
Why?
|
| Aging | 2 | 2024 | 745 | 0.050 |
Why?
|
| Prevalence | 2 | 2005 | 1386 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2009 | 6 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 315 | 0.050 |
Why?
|
| Medical Records | 1 | 2002 | 137 | 0.050 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2001 | 15 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 77 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 235 | 0.040 |
Why?
|
| Logistic Models | 1 | 2005 | 1277 | 0.040 |
Why?
|
| Thyroid Crisis | 1 | 2001 | 5 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 52 | 0.040 |
Why?
|
| Antithyroid Agents | 1 | 2001 | 19 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 1996 | 1536 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2001 | 204 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 174 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2005 | 869 | 0.040 |
Why?
|
| Cell Line | 3 | 2010 | 2040 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 3 | 1994 | 6 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2001 | 78 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2003 | 496 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2001 | 137 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 722 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 981 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2001 | 220 | 0.040 |
Why?
|
| Culture Media | 1 | 2000 | 79 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 2574 | 0.040 |
Why?
|
| Flavonoids | 1 | 2000 | 75 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 232 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2001 | 123 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 211 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 694 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 1996 | 165 | 0.040 |
Why?
|
| Base Sequence | 3 | 1996 | 1331 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 542 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 1980 | 0.040 |
Why?
|
| United States | 2 | 2020 | 7850 | 0.040 |
Why?
|
| DNA Primers | 2 | 1996 | 292 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 489 | 0.040 |
Why?
|
| Zinc | 1 | 1999 | 92 | 0.040 |
Why?
|
| Addison Disease | 1 | 1998 | 3 | 0.040 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1998 | 3 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 694 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1998 | 21 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1996 | 1991 | 0.040 |
Why?
|
| Emergencies | 1 | 2018 | 121 | 0.030 |
Why?
|
| Rhode Island | 1 | 2017 | 100 | 0.030 |
Why?
|
| Complement Factor D | 1 | 1996 | 4 | 0.030 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1996 | 4 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1996 | 12 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 1996 | 92 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 1996 | 84 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1996 | 156 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1996 | 171 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2018 | 6679 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1996 | 152 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 1994 | 1 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 215 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 1994 | 5 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1994 | 22 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1382 | 0.030 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 1993 | 1 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 394 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1993 | 84 | 0.030 |
Why?
|
| Middle Aged | 1 | 2010 | 17682 | 0.020 |
Why?
|
| Arginine | 1 | 1993 | 124 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 878 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 111 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1362 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 873 | 0.020 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2008 | 4 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4706 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 467 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3395 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 618 | 0.020 |
Why?
|
| Brain | 1 | 1994 | 1552 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 2463 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2181 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 331 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 499 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 1994 | 1276 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 732 | 0.010 |
Why?
|
| Liver | 2 | 1994 | 857 | 0.010 |
Why?
|
| Tritium | 1 | 1999 | 22 | 0.010 |
Why?
|
| Pentetic Acid | 1 | 1999 | 33 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1999 | 50 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 1999 | 70 | 0.010 |
Why?
|
| Epinephrine | 1 | 1998 | 45 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1999 | 394 | 0.010 |
Why?
|
| Perception | 1 | 1998 | 176 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1994 | 21 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 63 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1994 | 55 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1994 | 76 | 0.010 |
Why?
|
| Fasting | 1 | 1994 | 51 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1994 | 176 | 0.010 |
Why?
|
| Organ Size | 1 | 1994 | 170 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 216 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1994 | 195 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1993 | 7 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1993 | 10 | 0.010 |
Why?
|
| Mosaicism | 1 | 1993 | 30 | 0.010 |
Why?
|
| Testis | 1 | 1994 | 149 | 0.010 |
Why?
|
| Death, Sudden | 1 | 1993 | 30 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1994 | 203 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1993 | 143 | 0.010 |
Why?
|
| Genotype | 1 | 1994 | 662 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1994 | 895 | 0.010 |
Why?
|
| Phenotype | 1 | 1994 | 1206 | 0.010 |
Why?
|
| Lung | 1 | 1994 | 956 | 0.000 |
Why?
|